1. PATIENT INFORMATION
(Required)
NAME (First, MI, Last)
ADDRESS
CITY STATE ZIP CODE
E-MAIL
HOME PHONE CELL PHONE
WORK PHONE SEX M F DOB (MM/DD/YYYY)
2. INSURANCE INFORMATION
(Required. Include alpha prefix and suffix with policy and group# when applicable or provide a copy of insurance cards)
PRIMARY INSURANCE
CARDHOLDER
RELATIONSHIP TO CARDHOLDER
EMPLOYER INS. CO. PHONE
POLICY# GROUP#
SECONDARY INSURANCE
CARDHOLDER
RELATIONSHIP TO CARDHOLDER
EMPLOYER INS. CO. PHONE
POLICY# GROUP#
PRESCRIPTION DRUG INSURER
CARD/BIN# PHONE
(Please include alpha prefix and suffix with policy and group# when applicable)
3. PRESCRIBER INFORMATION
(Required. Verification of Benefits will be faxed to this Prescriber)
PRACTICE NAME OFFICE CONTACT
PRESCRIBER NAME (First, Last) SPECIALTY
ADDRESS
CITY STATE ZIP CODE
E-MAIL
PHONE FAX
MEDICAID/MEDICARE PROVIDER# TAX ID#
STATE LICENSE# UPIN/NPI#
4. CLINICAL INFORMATION FOR INVOKANA
®
(Required. Visit JanssenCarePath.com for ICD-10 codes or consult the ICD-10 code book for additional information)
DIAGNOSIS CODE: INDICATION:
DATE OF DIAGNOSIS OR YEARS WITH DISEASE
DOSAGE: 100-mg canagliflozin once daily 300-mg canagliflozin once daily
COMMENT/OTHER
5. CLINICAL INFORMATION FOR INVOKAMET
®
(Required. Visit JanssenCarePath.com for ICD-10 codes or consult the ICD-10 code book for additional information)
DIAGNOSIS CODE: INDICATION:
DATE OF DIAGNOSIS OR YEARS WITH DISEASE
DOSAGE: 50-mg canagliflozin/500-mg metformin HCl twice daily
150-mg canagliflozin/500-mg metformin HCl twice daily
50-mg canagliflozin/1000-mg metformin HCl twice daily
150-mg canagliflozin/1000-mg metformin HCl twice daily
COMMENT/OTHER
6. CLINICAL INFORMATION FOR INVOKAMET
®
XR
(Required. Visit JanssenCarePath.com for ICD-10 codes or consult the ICD-10 code book for additional information)
DIAGNOSIS CODE: INDICATION:
DATE OF DIAGNOSIS OR YEARS WITH DISEASE
DOSAGE: 50-mg canagliflozin/500-mg metformin HCl extended-release 2 tablets once daily
150-mg canagliflozin/500-mg metformin HCl extended-release 2 tablets once daily
50-mg canagliflozin/1000-mg metformin HCl extended-release 2 tablets once daily
150-mg canagliflozin/1000-mg metformin HCl extended-release 2 tablets once daily
COMMENT/OTHER
7. CLINICAL INFORMATION FOR XARELTO
®
(Required. Visit JanssenCarePath.com for ICD-10 codes or consult the ICD-10 code book for additional information)
DIAGNOSIS CODE: INDICATION:
DATE OF PROCEDURE
DOSAGE: 2.5-mg 10-mg 15-mg 20-mg 30-day Starter Pack*
*XARELTO
®
Starter Pack includes 15-mg twice daily for first 21 days; 20-mg once daily for Days 22-30.
COMMENT/OTHER
8. PRIOR AUTHORIZATION
(Please check the appropriate box[es] below to request assistance with prior authorizations)
Prior Authorization Form Assistance By checking this box, I request that Janssen CarePath assist my office in providing the
requirements of this patient’s health plan related to prior authorization for treatment with the medication specified above. I
understand that assistance includes obtaining the health plan-specific prior authorization form, and completing it based upon
the patient-specific information provided on this form. I understand that the partially completed prior authorization form will
be provided to the office for completion and submission in the office’s sole discretion.
Prior Authorization Status Monitoring By checking this box, I request that Janssen CarePath actively monitor the status
of the prior authorization submission. I request that Janssen CarePath provide status updates to my office with respect to this
patient’s prior authorization for treatment with the specified medication.
Benefits Investigation Form
Complete and fax this form to 855-227-3721 or mail to 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.
For assistance, call 877-CarePath (877-227-3728), Monday–Friday, 8:00
am–8:00 pm ET.
UPDATE 9.20
© Janssen Pharmaceuticals, Inc. 2020 September 2020 cp-54062v5
Janssen CarePath cannot accept any information without an executed Business Associate Agreement or Patient Authorization Form, which can be found at JanssenCarePath.com or as the last page of this document.
Please read full Prescribing Information for INVOKANA® and Medication Guide for INVOKANA®. Please read full
Prescribing Information, including Boxed Warning(s), for INVOKAMET®/INVOKAMET® XR and XARELTO®, and
Medication Guides for INVOKAMET®/INVOKAMET® XR and XARELTO®. Provide the appropriate Medication Guide to
your patients and encourage discussion.
Clear Form
Print Form
© Janssen Pharmaceuticals, Inc. 2020 September 2020 cp-54062v5
By providing your information and information about your patient on the front of the Benefits Investigation Form, you are requesting the services described on this form. The information
you provide will only be used by Janssen Pharmaceuticals, Inc., our affiliates, and our service providers involved in delivering these services. You may withdraw your request for these
services by calling 877-CarePath (877-227-3728). Our Privacy Policy, available at JanssenCarePath.com/Privacy-Policy, governs the use of the information you provide. By providing
the information and submitting this form, you indicate you read, understand, and agree to these terms.
Patient insurance benefits investigation and other Janssen CarePath program offerings are provided by third-party service providers for Janssen CarePath, under contract with Johnson
& Johnson Health Care Systems Inc. on behalf of Janssen Pharmaceuticals, Inc., Janssen Biotech, Inc., and Janssen Products, LP (Janssen). Janssen CarePath is not available to patients
participating in the Patient Assistance Program offered by Johnson & Johnson Patient Assistance Foundation. The availability of information and assistance may vary based on the Janssen
medication, geography and other program differences. Janssen CarePath assists healthcare providers in the determination of whether treatment could be covered by the applicable
third-party payer based on coverage guidelines provided by the payer, and patient information provided by the healthcare provider under appropriate authorization following the
provider’s exclusive determination of medical necessity. This information and assistance are made available as a convenience to patients, and there is no requirement that patients or
HCPs use any Janssen product in exchange for this information or assistance. Janssen assumes no responsibility for and does not guarantee the quality, scope, or availability of the
information and assistance provided. The third-party service providers, not Janssen, are responsible for the information and assistance provided under this program. Each HCP and patient
is responsible for verifying or confirming any information provided. All claims and other submissions to payers should be in compliance with all applicable requirements.
Janssen CarePath
2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560
Fax 855-227-3721
Janssen CarePath Patient Authorization
Patients should read the Patient Authorization and sign electronically or download, print, and sign.
Completed form may be uploaded to Patient Account or Provider Portal, faxed to Janssen CarePath at 855-227-3721, or mailed to address below.
Patients can access a copy of completed form in their Janssen CarePath Account – My Profile.
My signature on this Patient Authorization Form confirms that I authorize each of my physicians, pharmacists, including any specialty pharmacy that receives my prescription for a
Janssen medication and other healthcare providers (together, “Healthcare Providers”) and each of my health insurers (together, “Insurers”) to disclose my protected health information,
including but not limited to information related to my medical condition and treatment, my health insurance coverage, my name, address, telephone number, insurance plan and/or
group numbers (together, “Protected Health Information”) to Johnson & Johnson Health Care Systems Inc., its affiliated companies, agents and representatives (together, “Janssen”),
including providers of alternate sources of funding for prescription drug costs, and other approved service providers authorized to manage, administer, and/or support Janssen
CarePath programs, Janssen CarePath Account for Patients, and Provider Portal for their Healthcare Providers for the purposes described below.
Specifically, I authorize Janssen to receive, use, and disclose my Protected Health Information in order to (i) enroll me in, determine my eligibility for, and contact me about, Janssen
medication support programs; (ii) provide me with educational materials, information, and services related to my Janssen medication; (iii) verify, investigate, assist with, and coordinate
my coverage for my Janssen medication with my Insurers; (iv) coordinate prescription fulfillment; (v) assist with analyses related to the quality, efficacy, and safety of my Janssen
medication, and patient access to and adherence to my Janssen medication; (vi) to share and provide access to, information generated by Janssen CarePath that may be useful for my
care, and; (vii) to improve, develop, and evaluate Janssen CarePath, its offerings, and materials. I also understand that pharmacies that ship my medication may be paid to share this
information with Janssen CarePath to help provide the offerings requested for me. Furthermore, I understand that my Protected Health Information will not be used or disclosed by
Janssen for any other purpose without my prior authorization unless permitted by law or unless information that specifically identifies me is removed. I understand that Janssen will
make every effort to keep my information private. Further, I understand that if my information is accidentally shared, federal privacy laws do not require that the person/party receiving
it not disclose the information further and that such information provided to a third party may no longer be protected by federal privacy laws.
I understand that I am not required to sign this Patient Authorization Form. My choice about whether to sign will not change the way my Healthcare Providers or Insurers treat me. If I
refuse to sign the Patient Authorization Form, or revoke my authorization later, I understand that this means I will not be able to participate or receive assistance from Janssen CarePath.
This authorization will last until I am no longer participating in Janssen CarePath, or accessing my Janssen CarePath Account. I understand that I may cancel or revoke this Authorization
at any time by mailing a letter requesting such cancellation to Janssen CarePath, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560 or by informing my Healthcare Providers
and Insurers in writing that I do not want them to share any information with Janssen. I further understand that cancellation or revocation will not affect Janssen’s ability to use and
disclose Protected Health Information that it has received prior to its receipt of my cancellation and revocation of participation in the program. My authorization will also end if Janssen
CarePath support programs or the Janssen CarePath Account is discontinued. Furthermore, I understand that I have the right to see or copy the Protected Health Information my
Healthcare Providers or Insurers have given to Janssen.
Patient name: Date of birth (mm/dd/yyyy):
Patient address: City: State: ZIP Code:
Patient sign here: Date:
If the patient cannot sign, patient’s legally authorized representative must sign below:
By: Date:
(Signature of person legally authorized to sign for patient)
Describe relationship to patient and authority to make medical decisions for patient:
© Janssen Pharmaceuticals, Inc. 2020 September 2020 cp-54062v5
Clear Form
Print Form